This study aimed to determine whether the proportion of female patients enrolled at individual clinical trial sites differed according to site principal investigator (PI) gender in industry-sponsored multicenter vascular trials. A retrospective, secondary, site-level analysis of seven completed Penumbra, Inc. (Alameda, CA, USA)-sponsored trials across neurovascular, peripheral, and coronary interventions was conducted. Sites were categorized as led by a female PI, a male PI with ≥1 female sub-investigator, or a male PI with no female investigators. Nonparametric tests, linear regression with trial-level fixed effects, and resampling-based sensitivity analyses were used to assess the association between PI gender and female enrollment. Given the small number of female-led sites, all findings were treated as exploratory. Across 230 sites (N = 3114 patients), trial-level female enrollment ranged from 23.8
To perform a systematic review and meta-analysis comparing efficacy and the safety profile of Degradable Starch Microspheres TACE (DSM-TACE) with conventional treatments (cTACE and DEB-TACE) in patients with Hepatocellular carcinoma (HCC). Comparative studies (including randomized controlled trials -RCTs- and observational studies) reporting at least one of the following outcomes were included and considered for statistical analysis: Tumor response according to mRECIST criteria, Overall Survival (OS), Adverse Events (AEs), increase of ALT and AST levels. Risk Ratios were calculated using random-effects models. Survival analyses and Hazard Ratios were derived using reconstructed individual patient data. 6/180 articles met inclusion criteria, including 1 RCT and 5 observational studies. Tumor response was comparable between DSM-TACE and control groups, without significant differences in the pooled analyses. DSM-TACE was not associated with a significant improvement in OS compared with conventional treatments (HR = 1.04; 95
Pain control and early mobility remain primary challenges after Total Knee Arthroplasty (TKA). This study will evaluate whether pre-TKA CT-guided cryoneurolysis of the genicular nerves improves postoperative pain, mobility, and quality of life in patients with knee osteoarthritis. One hundred patients undergoing unilateral TKA will be randomized 1:1 in this prospective, open-label trial. Intervention patients will receive CT-guided cryoneurolysis of three genicular nerves (superior medial, superior lateral, and inferior medial) 24–72h before surgery; controls will undergo TKA alone. Chronic opioid users and patients unable to self-assess are excluded. Perioperative analgesia and rehabilitation will be standardized. Patients will be assessed preoperatively and at 1, 3, 6, and 12 months using the Brief Pain Inventory (BPI), Knee Injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Quality of Life Index (QLI). The primary endpoint is the BPI Pain Interference Scale at 3 months; secondary endpoints include KOOS, WOMAC, and QLI scores, opioid consumption (morphine milligram equivalents), time to mobilization, and length of stay. Safety endpoints comprise adverse events of either procedure, graded by the modified CIRSE classification. One hundred patients provide >80
Interventional radiology (IR) services for children lag behind IR provision for adults. Meanwhile, visibility of the paediatric IR (PIR) services that are currently available is limited. The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Paediatric Taskforce mandate included the mapping of current PIR services via a member survey. A survey questionnaire comprising 17 questions was created by the CIRSE Paediatric Taskforce. All CIRSE members were invited by email to participate. Responses were collected over a three-month period, and results were analysed in a descriptive manner. In total, 293 responses were received from a total of 8111 CIRSE members who were contacted. The 293 respondents were employed in 235 medical institutions across 59 countries. A large majority of institutions reported performing less than 50 PIR procedures per month, most of which were image-guided biopsies, sclerotherapy and vascular access procedures. Procedures were performed by a variety of medical specialists including paediatric interventional radiologists, adult interventional radiologists, and non-radiologists. A lack of structured PIR training was reported by most respondents, together with a request to increase PIR training and network options across Europe. The survey results provide a structured mapping of PIR provision within a multinational IR organisation. The lack of structured training programmes and resources demonstrate a clear mission to expand PIR training and service development in order to widen access to minimal-invasive care for children.
To systematically review the literature and perform a meta-analysis assessing the efficacy and safety of N-butyl cyanoacrylate (NBCA) glue diluted with Lipiodol for vascular embolization. A systematic search of MEDLINE/PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) identified studies published between January 2004 and May 2024. Data were independently extracted and evaluated by two reviewers. Studies reporting efficacy and/or safety outcomes in ≥10 patients treated with NBCA–Lipiodol® Ultra Fluid alone were included. The primary outcome was the overall rate of technically successful embolization, defined as immediate haemostasis or complete occlusion; secondary outcomes included technical success by indication, recurrent bleeding, clinical success by indication, defined according to each indication, and procedure-related complications, including reported major complications. A total of 150 studies involving 8996 patients were included: 132 peripheral (8301 patients) and 18 central (695 patients) embolization studies. Outcomes varied across indications. Technical success ranged from 94.1
To determine the publication rate of oral presentations from the CIRSE 2021 and 2022 congresses, assess time to publication and citation impact, and identify factors associated with successful full-text publication in PubMed/MEDLINE-indexed journals. This cross-sectional bibliometric study analyzed all oral presentations from the CIRSE 2021 and 2022 Books of Abstracts. Publication searches were conducted using Google Scholar and PubMed/MEDLINE between February and March 2026. The primary endpoint was the publication rate. Secondary endpoints included time to publication, citation count, 5-year journal impact factor (JIF), and factors associated with publication. Of 254 oral abstracts, 158 (62.2
Jetstream atherectomy is commonly used to prepare severely calcified femoropopliteal lesions; however, the optimal choice between low- and high-dose drug-coated balloons after atherectomy remains unclear. We analyzed data from multicenter JOKER registry. We identified patients with symptomatic lower-extremity artery disease who underwent Jetstream atherectomy followed by DCB angioplasty for severely calcified femoropopliteal lesions between November 2022 and December 2024. Patients were classified into the low-dose drug-coated balloon group, treated with Ranger, and the high-dose drug-coated balloon group, treated with IN.PACT Admiral. Propensity score matching was used for adjustment for clinical and lesion characteristics. The primary endpoint was 1-year primary patency. Of 219 patients, 136 were treated with low-dose drug-coated balloon and 83 with high-dose drug-coated balloon. Propensity score matching generated 66 matched pairs. In the matched cohort, flow impairment after Jetstream atherectomy did not differ significantly between the low-dose and high-dose drug-coated balloon groups (16.7
To investigate the clinical outcomes of the E-liac (Artivion©) Iliac Branched Device (IBD) in mid- to long-term follow-up. This retrospective multicentre observational study included all patients treated with the E-liac (Artivion©) IBD in the participating centres between January 2011 and December 2024. Patients treated for acute ruptured aneurysm were excluded. IBD was indicated for isolated iliac aneurysm, as treatment for type 1b endoleak or in combination with EVAR for aorto-iliac aneurysm. Primary outcome was technical success, defined as deploying the IBD as planned while maintaining flow in the internal and external iliac arteries (IIA, EIA), without type 1 or 3 endoleak extending beyond 30 days and without mortality within 30 days. A subgroup of patients with at least 60 months of follow-up was analysed separately. A total of 252 E-liac IBDs were deployed in 221 patients. One hundred and seventy-one IBDs (67.9
Bronchoscopic microwave ablation (MWA) is an emerging therapy for peripheral pulmonary lesions. Clinical cohorts evaluating the Ion robotic-assisted bronchoscopy (RAB) system for MWA remain lacking. We report our initial prospective experience with Ion RAB-guided MWA using an augmented fluoroscopy (AF) workflow, benchmarked against a historical electromagnetic navigation bronchoscopy (ENB) cohort. This prospective single-center cohort study evaluated 21 consecutive patients prospectively enrolled to undergo microwave ablation (MWA) for peripheral pulmonary lesions using the Ion RAB system (25 lesions) between January 1, 2025, and January 1, 2026, and benchmarked these outcomes against a retrospectively established historical cohort of 42 consecutive ENB-guided MWA procedures (51 lesions) performed at the same center under an augmented fluoroscopy (AF) strategy. The primary endpoint was postoperative day 1 (POD1) technical success. Secondary endpoints included 6-month treatment success, navigation/total workflow times, cone-beam CT (CBCT) acquisitions, radiation dose, and complications. POD1 technical success was 100
To describe the clinical decision-making underlying the selection of the percutaneous ablation modality for bone tumors. Two experienced interventional radiologists designed in consensus a model for ablation modality selection. Consecutive patients with primary and metastatic bone tumors were retrospectively identified. Demographic, clinical, and imaging data were collected for each tumor. The dataset was randomly divided into a training set (618/926 tumors; 66.7
